Lupus Clinical Trials and the Promise of Future Therapies

Overview

Journal Rheumatol Immunol Res

Specialty Allergy & Immunology

Date 2023 Oct 2

PMID 37781678

Authors

Leila Khalili

Wei Tang

Anca D Askanase

Affiliations

Soon will be listed here.

References

Thanou A, Chakravarty E, James J, Merrill J . How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. Rheumatology (Oxford). 2014; 53(12):2175-81. PMC: 4542656. DOI: 10.1093/rheumatology/keu153. View

Dyball S, Collinson S, Sutton E, McCarthy E, Bruce I, Parker B . Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR). Lupus Sci Med. 2021; 8(1). PMC: 8311338. DOI: 10.1136/lupus-2021-000513. View

Felten R, Sagez F, Gavand P, Martin T, Korganow A, Sordet C . 10 most important contemporary challenges in the management of SLE. Lupus Sci Med. 2019; 6(1):e000303. PMC: 6340557. DOI: 10.1136/lupus-2018-000303. View

Tanaka S, Zheng S, Kharel Y, Fritzemeier R, Huang T, Foster D . Sphingosine 1-phosphate signaling in perivascular cells enhances inflammation and fibrosis in the kidney. Sci Transl Med. 2022; 14(658):eabj2681. PMC: 9873476. DOI: 10.1126/scitranslmed.abj2681. View

Morand E, Vital E, Petri M, van Vollenhoven R, Wallace D, Mosca M . Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023; 401(10381):1001-1010. DOI: 10.1016/S0140-6736(22)02607-1. View

van Vollenhoven R, Kalunian K, Dorner T, Hahn B, Tanaka Y, Gordon R . Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. 2022; 81(11):1556-1563. PMC: 9606504. DOI: 10.1136/ard-2022-222858. View

Morand E, Furie R, Tanaka Y, Bruce I, Askanase A, Richez C . Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2019; 382(3):211-221. DOI: 10.1056/NEJMoa1912196. View

Arnaud L, Tektonidou M . Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford). 2020; 59(Suppl5):v29-v38. PMC: 7719040. DOI: 10.1093/rheumatology/keaa382. View

Mysler E, Spindler A, Guzman R, Bijl M, Jayne D, Furie R . Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013; 65(9):2368-79. DOI: 10.1002/art.38037. View

10.

Rovin B, Furie R, Latinis K, Looney R, Fervenza F, Sanchez-Guerrero J . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64(4):1215-26. DOI: 10.1002/art.34359. View

11.

Burg N, Salmon J, Hla T . Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases. Nat Rev Rheumatol. 2022; 18(6):335-351. PMC: 9641499. DOI: 10.1038/s41584-022-00784-6. View

12.

Izmirly P, Parton H, Wang L, McCune W, Lim S, Drenkard C . Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021; 73(6):991-996. PMC: 8169527. DOI: 10.1002/art.41632. View

13.

Furie R, Aroca G, Cascino M, Garg J, Rovin B, Alvarez A . B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2021; 81(1):100-107. PMC: 8762029. DOI: 10.1136/annrheumdis-2021-220920. View

14.

Yee C, Farewell V, Isenberg D, Rahman A, Teh L, Griffiths B . British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 2007; 56(12):4113-9. PMC: 2659367. DOI: 10.1002/art.23130. View

15.

Rovin B, Teng Y, Ginzler E, Arriens C, Caster D, Romero-Diaz J . Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10289):2070-2080. DOI: 10.1016/S0140-6736(21)00578-X. View

16.

Piga M, Arnaud L . The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?. J Clin Med. 2021; 10(2). PMC: 7827672. DOI: 10.3390/jcm10020243. View

17.

Furie R, Rovin B, Houssiau F, Malvar A, Teng Y, Contreras G . Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020; 383(12):1117-1128. DOI: 10.1056/NEJMoa2001180. View

18.

DallEra M, Bruce I, Gordon C, Manzi S, McCaffrey J, Lipsky P . Current challenges in the development of new treatments for lupus. Ann Rheum Dis. 2019; 78(6):729-735. DOI: 10.1136/annrheumdis-2018-214530. View

19.

Knapke J, Snyder D, Carter K, Fitz-Gerald M, Fritter J, Kolb H . Issues for recruitment and retention of clinical research professionals at academic medical centers: Part 1 - collaborative conversations Un-Meeting findings. J Clin Transl Sci. 2022; 6(1):e80. PMC: 9305083. DOI: 10.1017/cts.2022.411. View

20.

Furie R, van Vollenhoven R, Kalunian K, Navarra S, Romero-Diaz J, Werth V . Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus. N Engl J Med. 2022; 387(10):894-904. DOI: 10.1056/NEJMoa2118025. View